Accelerating Malignant Tumor Research through Joint Research with the National Cancer Center
First written in FY2016-Q3. 6 of 10 entries say "Restated". Latest entry: FY2020-Q1.
1 other company's latest entry also says "Restated".
- FY2020-Q1RestatedAnnual report
「In the “malignant tumor project (target molecule: FSTL1),” we are conducting joint research with the National Cancer Center. While analyzing FSTL1 expression in various human malignant tumor tissues and conducting antitumor studies on various malignant tumor cell lines using our antibodies against FSTL1, we will continue partnership negotiations with pharmaceutical companies.」
Through joint research with the National Cancer Center, we are advancing FSTL1 expression analysis and antitumor studies while continuing partnership negotiations with pharmaceutical companies. - FY2019-Q3AdvancedAnnual report
「In the “malignant tumor project (target molecule: FSTL1),” we are continuing joint research with the National Cancer Center. We are sequentially analyzing FSTL1 expression in various human malignant tumor tissues and other samples held in large quantities by the Center. In parallel, we are conducting antitumor studies on various malignant tumor cell lines using our anti-FSTL1 antibodies.」
In addition to the existing analysis of FSTL1 expression in human malignant tumor tissues, we are conducting parallel antitumor studies on malignant tumor cell lines using anti-FSTL1 antibodies. - FY2019-Q2AdvancedAnnual report
「Contract date: 30 November 2018. Contract period: 1 December 2015 to 30 November 2019. Main contract terms: Our group and the National Cancer Center, an independent administrative agency, will conduct joint research on the development of therapeutic antibody drugs for malignant tumors using chicken antibody production technology. (Extension of the original contract period)」
The joint research agreement with the National Cancer Center was extended from the original agreement, with the contract period running through 30 November 2019. - FY2019-Q1RestatedAnnual report
「In the “malignant tumor project (target molecule: FSTL1),” we are conducting joint research with the National Cancer Center. While sequentially analyzing FSTL1 expression in various human malignant tumor tissues held in large quantities by the Center, we will continue joint research and partnership negotiations with pharmaceutical companies.」
We are continuing FSTL1 expression analysis with the National Cancer Center and partnership negotiations with pharmaceutical companies. - FY2018-Q3RestatedAnnual report
「In the “malignant tumor project,” as part of our joint research with the National Cancer Center, we are conducting sequential expression analyses of FSTL1 in various human malignant tumor tissues held in large quantities by the Center. Across all projects, we are pursuing joint research with public research institutions while continuing partnership negotiations with multiple domestic and overseas pharmaceutical companies.」
We are continuing FSTL1 expression analysis with the National Cancer Center, joint research with public research institutions, and partnership negotiations with pharmaceutical companies. - FY2018-Q2RestatedAnnual report
「In the “malignant tumor project,” as part of our joint research with the National Cancer Center, we are conducting sequential expression analyses of FSTL1 in various human malignant tumor tissues held in large quantities by the Center. Across all projects, we are pursuing joint research with public research institutions while continuing partnership negotiations with multiple domestic and overseas pharmaceutical companies.」
We are continuing FSTL1 expression analysis with the National Cancer Center, joint research with public research institutions, and partnership negotiations with pharmaceutical companies. - FY2018-Q1AdvancedAnnual report
「For the “malignant tumor project,” we entered into a joint research agreement with the National Cancer Center at the end of 2015 and conducted efficacy confirmation studies in disease-model animals. We are currently conducting sequential expression analyses of FSTL1 in various human malignant tumor tissues held in large quantities by the Center.」
In the joint research with the National Cancer Center, specific research activities have progressed from efficacy confirmation studies in disease-model animals to FSTL1 expression analysis in human malignant tumor tissues. - FY2017-Q3RestatedAnnual report
「For these 3 projects, we are pursuing joint research with public research institutions, including the National Cancer Center, while continuing partnership negotiations with multiple domestic and overseas pharmaceutical companies.」
We are continuing joint research with public research institutions and partnership negotiations with multiple domestic and overseas pharmaceutical companies. - FY2017-Q2RestatedAnnual report
「In particular, for the “malignant tumor project,” we are pursuing joint research with the National Cancer Center while continuing partnership negotiations with multiple domestic and overseas pharmaceutical companies.」
We are continuing joint research with the National Cancer Center while pursuing partnership negotiations with pharmaceutical companies. - FY2016-Q3First statedAnnual report
「In addition, since January this year, we have been advancing the work as joint research with the National Cancer Center, accelerating research and development.」
Since January 2016, we have conducted joint research with the National Cancer Center and accelerated research and development for the malignant tumor project.